Innate Pharma

AGM Information • Jun 23, 2009

INNATE PHARMA ANNOUNCES THE OUTCOME OF ITS ANNUAL GENERAL MEETING, INCLUDING CHANGES IN THE COMPOSITION OF ITS SUPERVISORY BOARD

• Innate Pharma held its annual general meeting on June 23, 2009
• All proposed resolutions were voted according to management's recommendations
• Mrs. Irina Staatz-Granzer joins the Supervisory Board as a new, independent member
• Mr. Patrick Van Beneden, from GIMV, an investor, is appointed as observer to the Supervisory Board for a one-year period

Marseilles, France, June 23, 2009

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today the outcome of its annual general meeting ("AGM") that took place on June 23, 2009, in Marseilles, France.

A number of 16,959,165 votes were expressed out of a total of 25,912,259 voting rights, representing a quorum of 65.4%. A total of 98 shareholders casted a vote. All resolutions were eventually voted in accordance with the management's recommendations and by a large majority of shareholders. Details of the votes will be available as of tomorrow on Innate Pharma's website, investors section (www.innate-pharma.com).

Mrs. Irina Staatz-Granzer, PhD, Pharmacist, a German national, was appointed as a new independent member of the Supervisory Board. During her career, Mrs Staatz-Granzer held several positions in the pharmaceutical industry, mostly in Business Development at Hermal, Boots Healthcare International, Knoll, Scil Biomedicals and as CEO (Scil Technology). She founded and is currently CEO of Staatz Business Development & Strategy and within this frame organised the trade sale of U3 Pharma, a German biotechnology company focused on cancer, to Daiichi Sankyo (a Japanese Pharmaceutical company) in 2008.

Mr. Frank Bulens, from GIMV, a Belgian investment firm, historical shareholder of the Company, has left the Supervisory Board. Mr. Patrick Van Beneden, also from GIMV, was appointed as an observer to the Supervisory Board for a period of one year.

"I am very pleased to join the Supervisory Board of Innate Pharma" stated Irina Staatz-Granzer. "I hope that my previous experiences will be useful for Innate Pharma as the Company enters an interesting period with significant news flow ahead".

"Alongside with the founders, managers and Board members at Innate Pharma, I would like to first thank Frank Bulens for his support and advice during is tenure at our Supervisory Board" said Hervé Brailly, CEO of Innate Pharma. He added: "I am now delighted to welcome Irina Staatz-Granzer and Patrick van Beneden to our board. We are convinced that these new additions to the Company will be instrumental in its maturation".

About Innate Pharma:

Innate Pharma S.A. ("the company") is a clinical-stage biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and other severe diseases. Founded in 1999, the company listed on NYSE-Euronext in Paris in 2006.

The company has significant expertise in identifying new targets and bringing novel drug candidates through to clinical proof-of-concept trials. It currently has seven proprietary drug candidates in development (two of which are in clinical trials with lead compound in Phase II clinical trial) and two programs out-licensed to Novo Nordisk A/S.

Based in Marseilles, France, Innate Pharma had 88 employees as at March 31, 2009.

Learn more about Innate-Pharma at www.innate-pharma.com

Practical Information about Innate Pharma shares:

ISIN code FR0010331421

Ticker code

IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Laure-Hélène Mercier, Director, Investor Relations Phone: +33 (0)4 30 30 30 87 Mobile: +33 (0)6 64 18 99 59 lmercier@innate-pharma.fr caroline@alizerp.com

Innate Pharma Alize Public Relations

Caroline Carmagnol Phone: +33 (0)1 41 22 07 31